LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial

BACKGROUND: Doravirine (DOR) is a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI). In the phase 3 DRIVE-AHEAD trial in HIV-1-infected treatment-naïve adults, DOR demonstrated noninferior efficacy to efavirenz (EFV) and favorable profiles for neuropsychiatric tolerability and lipids at 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Orkin, Chloe, Squires, Kathleen, Molina, Jean-Michel, Sax, Paul, Wong, Wingwai, Sussmann, Otto, Lin, Gina, Kumar, Sushma, Hanna, George, Hwang, Carey, Martin, Elizabeth, Teppler, Hedy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253652/
http://dx.doi.org/10.1093/ofid/ofy229.2175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253652/
http://dx.doi.org/10.1093/ofid/ofy229.2175

Ejemplares similares